GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Orexo AB (FRA:C5G) » Definitions » Cyclically Adjusted Price-to-FCF

Orexo AB (FRA:C5G) Cyclically Adjusted Price-to-FCF : (As of Jun. 04, 2025)


View and export this data going back to 2018. Start your Free Trial

What is Orexo AB Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Orexo AB Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Orexo AB's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orexo AB Cyclically Adjusted Price-to-FCF Chart

Orexo AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Orexo AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Orexo AB's Cyclically Adjusted Price-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Orexo AB's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Orexo AB's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Orexo AB's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Orexo AB's Cyclically Adjusted Price-to-FCF falls into.


;
;

Orexo AB Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Orexo AB's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Orexo AB's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0.087/132.8245*132.8245
=0.087

Current CPI (Mar. 2025) = 132.8245.

Orexo AB Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 -0.114 99.995 -0.151
201509 -0.248 100.228 -0.329
201512 -0.005 100.276 -0.007
201603 0.104 100.751 0.137
201606 0.061 101.019 0.080
201609 0.091 101.138 0.120
201612 0.212 102.022 0.276
201703 0.085 102.022 0.111
201706 0.144 102.752 0.186
201709 0.277 103.279 0.356
201712 -0.069 103.793 -0.088
201803 0.302 103.962 0.386
201806 0.105 104.875 0.133
201809 0.065 105.679 0.082
201812 0.196 105.912 0.246
201903 0.137 105.886 0.172
201906 0.118 106.742 0.147
201909 0.323 107.214 0.400
201912 0.104 107.766 0.128
202003 0.115 106.563 0.143
202006 -0.313 107.498 -0.387
202009 -0.174 107.635 -0.215
202012 -0.118 108.296 -0.145
202103 -0.184 108.360 -0.226
202106 -0.098 108.928 -0.119
202109 -0.288 110.338 -0.347
202112 -0.236 112.486 -0.279
202203 -0.187 114.825 -0.216
202206 0.027 118.384 0.030
202209 -0.168 122.296 -0.182
202212 -0.161 126.365 -0.169
202303 -0.162 127.042 -0.169
202306 -0.059 129.407 -0.061
202309 -0.070 130.224 -0.071
202312 -0.009 131.912 -0.009
202403 -0.052 132.205 -0.052
202406 -0.024 132.716 -0.024
202409 -0.034 132.304 -0.034
202412 0.014 132.987 0.014
202503 0.087 132.825 0.087

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Orexo AB  (FRA:C5G) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Orexo AB Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Orexo AB's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Orexo AB Business Description

Industry
Traded in Other Exchanges
Address
Virdings alle 32 A, P.O. Box 303, Uppsala, SWE, 75105
Orexo AB has operations in Sweden and the United States. Operations are monitored and presented in the segments USA Pharma, Digital Therapeutics (DTx), and HQ & Pipeline. The majority is from the USA Pharma segment. Geographically, the majority is derived from the United States. USA Pharma includes the commercialization of fully owned pharmaceuticals in the United States market. Digital Therapeutics include the commercialization of Orexo's groundbreaking evidence-based digital therapeutics, mainly in the United States market, which is in an early development stage. HQ &Pipeline includes the Development of pharmaceuticals performed at Orexo's headquarters in Uppsala, Sweden.

Orexo AB Headlines

No Headlines